In BH3 profiling, cells are exposed to different BH3 mimetic peptides and cytochrome c release is measured; BH3 profiling has proven useful for investigating tumor dependency on selected BCL-2 antiapoptotic members for survival.18,19 While we found no difference in overall priming to BIM and PUMA between the parental and VEN-RE cells, we observed increased priming to the peptides NOXA-A, MS1, and HRK in VEN-RE cell lines, indicating increased dependence on antiapoptotic MCL-1 and BCL-XL, both of which are not targeted by VEN (Fig. 2c, Supplementary Fig. 2c, d). The gene discussed is BCL2L11; the disease is neoplasm.